
- The vaccine will be developed using virus strain. These virus strains are isolated at ICMR's National Institute of Virology (NIV), Pune.
- Work on vaccine development has been initiated between the two partners. ICMR-NIV will provide continuous support to BBIL for vaccine development. ICMR and BBIL will seek fast-track approvals to expedite vaccine development, subsequent animal studies, and clinical evaluation of the candidate vaccine, which will be fully indigenous to India.
- The initial process to develop vaccine has been started and for this ICMR has shared one of the 11 virus strains which it has managed to culture with Bharat Biotech.
Question:
a. GSK India
b. Mylab
c. Bharat Biotech
d. Bione